Exclusive: President and CEO of IntelGenX Discusses the Firm's Pending FDA Decision

(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 11/07/11 -- In an exclusive interview, Horst G. Zerbe, Ph.D., President and CEO of IntelGenX Corporation (OTCBB: IGXT) shares his thoughts on the firm's pending U.S. regulatory decision involving the drug candidate CPI-300.

CPI-300 is also known as INT0004, IntelGenX's new strength antidepressant bupropion hydrochloride -- an oral antidepressant drug of the aminoketone class which selectively inhibits the neuronal reuptake of dopamine, norepinephrine, and serotonin.

Some observers believe that while a CPI-300 approval can become a financial win for the company it may also prove to be a key symbolic victory; one showing that IntelGenX can develop a product from the bench through approval.

The full exclusive interview, including some of the catalysts investors should be looking for in 2012 as far as IntelGenX is concerned, is available now at:



In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:



News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com





Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 07.11.2011 - 13:52 Uhr
Sprache: Deutsch
News-ID 84538
Anzahl Zeichen: 0

contact information:
Town:

LOS ANGELES, CA

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 193 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Exclusive: President and CEO of IntelGenX Discusses the Firm's Pending FDA Decision"
steht unter der journalistisch-redaktionellen Verantwortung von

BioMedReports (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Why Zalicus (ZLCS) Shares Could Make a Big Move in the Days Ahead ...

LOS ANGELES, CA -- (Marketwired) -- 11/06/13 -- In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a huge binary event from Zalicus, Inc. (NASDAQ: ZLCS); a NASDAQ listed bioph ...

Discounted Price Levels Make CEL-SCI Shares a Solid Speculative "Buy" ...

LOS ANGELES, CA -- (Marketwired) -- 08/01/13 -- With shares trading at heavily discounted price levels, speculative investors looking for a good bottom bounce trade should have their sights set on CEL-SCI Corporation (NYSE MKT: CVM) who last provide ...

Q&A With Coronado Biosciences CEO Harlan Weisman, M.D. ...

LOS ANGELES, CA -- (Marketwired) -- 07/23/13 -- It has been over a year since Coronado Biosciences, and the company, so we thought it time for an updated Q&A on this biopharmaceutical company that continues to be one of biotech's most talk ...

Alle Meldungen von BioMedReports